AU2014230134A1 - Novel medicaments comprising an antibody composition enriched with predominant charge isoform - Google Patents

Novel medicaments comprising an antibody composition enriched with predominant charge isoform Download PDF

Info

Publication number
AU2014230134A1
AU2014230134A1 AU2014230134A AU2014230134A AU2014230134A1 AU 2014230134 A1 AU2014230134 A1 AU 2014230134A1 AU 2014230134 A AU2014230134 A AU 2014230134A AU 2014230134 A AU2014230134 A AU 2014230134A AU 2014230134 A1 AU2014230134 A1 AU 2014230134A1
Authority
AU
Australia
Prior art keywords
antibody
composition
monoclonal antibody
antibody composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014230134A
Other languages
English (en)
Inventor
Nicolas Bihoreau
Guillaume CHEVREUX
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of AU2014230134A1 publication Critical patent/AU2014230134A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2014230134A 2013-03-15 2014-03-14 Novel medicaments comprising an antibody composition enriched with predominant charge isoform Abandoned AU2014230134A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1352360 2013-03-15
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
PCT/EP2014/055179 WO2014140322A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Publications (1)

Publication Number Publication Date
AU2014230134A1 true AU2014230134A1 (en) 2015-10-29

Family

ID=48771615

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014230134A Abandoned AU2014230134A1 (en) 2013-03-15 2014-03-14 Novel medicaments comprising an antibody composition enriched with predominant charge isoform

Country Status (11)

Country Link
US (1) US20160046722A1 (https=)
EP (1) EP2968533A1 (https=)
JP (1) JP2016512216A (https=)
KR (1) KR20150132522A (https=)
CN (1) CN105163758B (https=)
AU (1) AU2014230134A1 (https=)
BR (1) BR112015023209A8 (https=)
CA (1) CA2907358A1 (https=)
FR (1) FR3003171B1 (https=)
MX (1) MX2015012812A (https=)
WO (1) WO2014140322A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729496B8 (en) 2011-07-06 2017-10-18 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
AU2017261142B2 (en) 2016-05-04 2022-03-10 Delaval Holding Ab A cartridge for a teatcup, and a teatcup
FR3053688A1 (fr) * 2016-07-06 2018-01-12 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
BR112021023438A2 (pt) * 2019-05-23 2022-01-11 Regeneron Pharma Caracterização de variantes de carga específica de domínio de anticorpos
CN114829407B (zh) * 2019-09-23 2024-06-21 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
WO2023041717A1 (en) 2021-09-16 2023-03-23 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
CN114236010A (zh) * 2021-12-18 2022-03-25 苏州莱奥生物技术有限公司 一种生物活性药物的药代动力学分析方法
CN115073548A (zh) * 2022-08-01 2022-09-20 上海蓝析生物技术有限公司 一种用于重组蛋白药物电荷异构体制备的缓冲体系

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230769B1 (hu) * 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
CN101928344B (zh) * 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
JP2006524039A (ja) * 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2729496B8 (en) * 2011-07-06 2017-10-18 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains

Also Published As

Publication number Publication date
EP2968533A1 (fr) 2016-01-20
BR112015023209A8 (pt) 2018-01-23
FR3003171B1 (fr) 2015-04-10
JP2016512216A (ja) 2016-04-25
CA2907358A1 (fr) 2014-09-18
FR3003171A1 (fr) 2014-09-19
WO2014140322A1 (fr) 2014-09-18
US20160046722A1 (en) 2016-02-18
CN105163758B (zh) 2017-11-17
BR112015023209A2 (pt) 2017-07-18
MX2015012812A (es) 2016-05-09
CN105163758A (zh) 2015-12-16
KR20150132522A (ko) 2015-11-25

Similar Documents

Publication Publication Date Title
US20160046722A1 (en) Novel medicaments comprising an antibody composition enriched with predominant charge isoform
TWI732176B (zh) 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
JP7811967B2 (ja) 互いに連結された２つの抗原結合ドメインを含む抗原結合分子
EP3119490B1 (en) In vitro prediction of in vivo half-life of antibodies
US10611843B2 (en) Anti-CD303 monoclonal antibodies
ES2619677T3 (es) Método de separación para anticuerpos fucosilados
EP4206223A1 (en) Heterodimer fc polypeptide
MX2013001336A (es) Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
JP2022514734A (ja) 抗ｔｒｅｍ２抗体の使用方法
JP2016504337A (ja) イオン交換クロマトグラフィーを使用して高マンノースグリコフォームのレベルを制御する方法
CN117715940A (zh) 抗trem-1抗体
EP2660324A1 (en) Production of secreted therapeutic antibodies in microalgae
TWI920354B (zh) 抗ｃｃｒ８抗體
RU2838581C2 (ru) Антигенсвязывающая молекула, содержащая два антигенсвязывающих домена, которые связаны друг с другом
US20190002567A1 (en) New use of an anti-cd303 transmembrane protein antibody
CN119552247A (zh) 抗cd25抗体及其医药用途
HK40093415A (zh) 具有改善的胞质溶胶穿透活性的抗原结合分子
HK40085483B (zh) 异二聚体fc多肽
HK40085483A (en) Heterodimer fc polypeptide
Kang Fc engineering for the reprogramming the effector functions of antibodies for improved therapeutic potency
HK40034272B (en) Fully human anti-b cell maturation antigen (bcma) single chain variable fragment, and application thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application